Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 21, 2023 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of...
Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of...
Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
August 30, 2023 06:00 ET
|
Outlook Therapeutics, Inc.
FDA issues Complete Response Letter (CRL) for ONS-5010 BLA based on CMC and need for further confirmatory clinical evidence Outlook Therapeutics working with FDA to address the Agency’s issues ...
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
August 14, 2023 08:05 ET
|
Outlook Therapeutics, Inc.
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration...
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
August 01, 2023 08:45 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of...
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
May 15, 2023 08:05 ET
|
Outlook Therapeutics, Inc.
Upcoming Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular...
Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
April 27, 2023 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank
March 13, 2023 07:00 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
February 14, 2023 08:05 ET
|
Outlook Therapeutics, Inc.
Pre-launch commercial activities underway as Company advances toward U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010 /...
Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference
February 07, 2023 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...